$140.42▲ 5.07 (3.75%)
Real-time prices · US MarketsHealthy balance sheet and financial position.
weak profitability metrics drag quality score.
Quality
4.4
Health
5
Growth
5
Valuation
4.7
Sentiment
5
Analyst Target
—
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
—
next 12 months est.
Market Cap
—
market capitalization
Div Yield
—
dividend yield
Profit Margin
—
net profit margin
Gross Margin
—
revenue minus COGS
ROE
—
return on equity
Beta
—
vs S&P 500
52-Week Range
$81 — $142
annual min — max
Frequently Asked Questions
What do analysts say about State Street SPDR S&P Biotech E right now?
State Street SPDR S&P Biotech E's Q·Score is 4.8/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
Is XBI overvalued or undervalued?
State Street SPDR S&P Biotech E (XBI) scores below peers on valuation metrics, trading above typical sector multiples.